drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00295 | DB12130 | 475 | 1,017 | [
"DDInter1244",
"DDInter1094"
] | Morphine | Lorlatinib | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
475,
24,
1017
]
],
[
[
475,
24,
976
],
[
976,
24,
1017
]
],
[
[
475,
25,
686
],
[
686,
24,
1017
]
],
[
[
475,
63,
529
],
[
529,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Morphine may lead to a major life threatening interaction when taken with Oxazepam and Oxazepam may cause a mode... |
DB00241 | DB08816 | 288 | 578 | [
"DDInter257",
"DDInter1802"
] | Butalbital | Ticagrelor | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
288,
24,
578
]
],
[
[
288,
24,
1135
],
[
1135,
62,
578
]
],
[
[
288,
24,
723
],
[
723,
24,
578
]
],
[
[
288,
24,
868
],
[
868,
6... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant... |
DB00047 | DB00524 | 176 | 811 | [
"DDInter932",
"DDInter1199"
] | Insulin glargine | Metolazone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
176,
24,
811
]
],
[
[
176,
24,
1605
],
[
1605,
40,
811
]
],
[
[
176,
24,
1014
],
[
1014,
1,
811
]
],
[
[
176,
24,
964
],
[
964,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Metola... |
DB00373 | DB00789 | 461 | 1,431 | [
"DDInter1809",
"DDInter796"
] | Timolol | Gadopentetic acid | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Moderate | 1 | [
[
[
461,
24,
1431
]
],
[
[
461,
63,
457
],
[
457,
40,
1431
]
],
[
[
461,
24,
808
],
[
808,
40,
1431
]
],
[
[
461,
21,
29018
],
[
29018,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadopentetic acid (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid (Compound) resembles Gadopenteti... |
DB00252 | DB00366 | 362 | 1,594 | [
"DDInter1460",
"DDInter600"
] | Phenytoin | Doxylamine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
362,
24,
1594
]
],
[
[
362,
25,
11
],
[
11,
1,
1594
]
],
[
[
362,
24,
662
],
[
662,
63,
1594
]
],
[
[
362,
35,
1376
],
[
1376,
6... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",... | Phenytoin may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Doxylamine (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate... |
DB00938 | DB08864 | 455 | 786 | [
"DDInter1635",
"DDInter1595"
] | Salmeterol | Rilpivirine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
455,
24,
786
]
],
[
[
455,
6,
8374
],
[
8374,
45,
786
]
],
[
[
455,
21,
28734
],
[
28734,
60,
786
]
],
[
[
455,
24,
918
],
[
918,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Salmeterol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Rilpivirine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when ta... |
DB00618 | DB09278 | 1,572 | 852 | [
"DDInter498",
"DDInter24"
] | Demeclocycline | Activated charcoal | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
1572,
24,
852
]
],
[
[
1572,
40,
964
],
[
964,
24,
852
]
],
[
[
1572,
1,
1545
],
[
1545,
24,
852
]
],
[
[
1572,
24,
1482
],
[
1482,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} m... | Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Demeclocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases... |
DB06176 | DB13139 | 1,342 | 1,032 | [
"DDInter1616",
"DDInter1063"
] | Romidepsin | Levosalbutamol | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1342,
24,
1032
]
],
[
[
1342,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
1342,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1342,
24,
124
],
[
124... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Romidepsin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantini... |
DB00023 | DB01276 | 305 | 123 | [
"DDInter127",
"DDInter706"
] | Asparaginase Escherichia coli | Exenatide | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
305,
24,
123
]
],
[
[
305,
24,
1463
],
[
1463,
23,
123
]
],
[
[
305,
24,
1072
],
[
1072,
24,
123
]
],
[
[
305,
24,
984
],
[
984,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases wh... |
DB01118 | DB09135 | 33 | 1,211 | [
"DDInter76",
"DDInter967"
] | Amiodarone | Ioxilan | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
33,
24,
1211
]
],
[
[
33,
25,
116
],
[
116,
63,
1211
]
],
[
[
33,
24,
1074
],
[
1074,
63,
1211
]
],
[
[
33,
63,
372
],
[
372,
25... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-13... | Amiodarone may lead to a major life threatening interaction when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may c... |
DB01095 | DB11986 | 671 | 484 | [
"DDInter769",
"DDInter648"
] | Fluvastatin | Entrectinib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
671,
24,
484
]
],
[
[
671,
63,
112
],
[
112,
23,
484
]
],
[
[
671,
24,
466
],
[
466,
62,
484
]
],
[
[
671,
63,
322
],
[
322,
24,... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide a... |
DB00278 | DB00569 | 291 | 553 | [
"DDInter117",
"DDInter775"
] | Argatroban | Fondaparinux | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Major | 2 | [
[
[
291,
25,
553
]
],
[
[
291,
21,
28681
],
[
28681,
60,
553
]
],
[
[
291,
23,
539
],
[
539,
62,
553
]
],
[
[
291,
24,
972
],
[
972,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
]
],
[
[
"Argatroban",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is cau... | Argatroban (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fondaparinux (Compound)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with... |
DB00220 | DB00635 | 798 | 1,573 | [
"DDInter1276",
"DDInter1515"
] | Nelfinavir | Prednisone | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
798,
24,
1573
]
],
[
[
798,
25,
175
],
[
175,
40,
1573
]
],
[
[
798,
24,
423
],
[
423,
40,
1573
]
],
[
[
798,
63,
1351
],
[
1351,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamci... | Nelfinavir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide and Ciclesonide (Compound) resembles Prednisone (Compound)
Nelfina... |
DB08868 | DB10315 | 1,011 | 1,137 | [
"DDInter737",
"DDInter1127"
] | Fingolimod | Measles virus vaccine live attenuated | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1011,
25,
1137
]
],
[
[
1011,
64,
1042
],
[
1042,
24,
1137
]
],
[
[
1011,
25,
119
],
[
119,
64,
1137
]
],
[
[
1011,
64,
273
],
[
273,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
... | Fingolimod may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Fingolimod may lead to a major life threatening interaction when taken with Talazoparib and ... |
DB04868 | DB11952 | 478 | 800 | [
"DDInter1293",
"DDInter612"
] | Nilotinib | Duvelisib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
478,
24,
800
]
],
[
[
478,
23,
466
],
[
466,
62,
800
]
],
[
[
478,
63,
222
],
[
222,
23,
800
]
],
[
[
478,
24,
310
],
[
310,
24,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutram... |
DB00618 | DB00900 | 1,572 | 45 | [
"DDInter498",
"DDInter544"
] | Demeclocycline | Didanosine | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Minor | 0 | [
[
[
1572,
23,
45
]
],
[
[
1572,
40,
1620
],
[
1620,
23,
45
]
],
[
[
1572,
1,
1669
],
[
1669,
62,
45
]
],
[
[
1572,
1,
1545
],
[
1545,
... | [
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Didanosine"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause... | Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Didanosine
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a minor interaction that can limit clinical effects when taken with D... |
DB00794 | DB05239 | 759 | 866 | [
"DDInter1521",
"DDInter425"
] | Primidone | Cobimetinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
759,
25,
866
]
],
[
[
759,
25,
214
],
[
214,
63,
866
]
],
[
[
759,
63,
888
],
[
888,
24,
866
]
],
[
[
759,
24,
1069
],
[
1069,
6... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u... | Primidone may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause... |
DB00215 | DB06209 | 1,230 | 256 | [
"DDInter388",
"DDInter1508"
] | Citalopram | Prasugrel | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
1230,
24,
256
]
],
[
[
1230,
6,
10215
],
[
10215,
45,
256
]
],
[
[
1230,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1230,
25,
752
],
[
752... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)"... | Citalopram (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Citalopram (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Citalopram may lead to a major life threatening interaction when taken with Cimetidine and Cimet... |
DB00420 | DB11113 | 508 | 657 | [
"DDInter1532",
"DDInter307"
] | Promazine | Castor oil | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
508,
24,
657
]
],
[
[
508,
24,
927
],
[
927,
63,
657
]
],
[
[
508,
24,
1491
],
[
1491,
24,
657
]
],
[
[
508,
25,
985
],
[
985,
2... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midos... |
DB08907 | DB15093 | 1,344 | 1,654 | [
"DDInter280",
"DDInter1698"
] | Canagliflozin | Somapacitan | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1344,
24,
1654
]
],
[
[
1344,
63,
168
],
[
168,
23,
1654
]
],
[
[
1344,
63,
176
],
[
176,
24,
1654
]
],
[
[
1344,
24,
1019
],
[
1019,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine... |
DB00220 | DB06228 | 798 | 792 | [
"DDInter1276",
"DDInter1609"
] | Nelfinavir | Rivaroxaban | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
798,
25,
792
]
],
[
[
798,
6,
4973
],
[
4973,
45,
792
]
],
[
[
798,
21,
28703
],
[
28703,
60,
792
]
],
[
[
798,
23,
752
],
[
752,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Rivaroxa... | Nelfinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound)
Nelfinavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidi... |
DB01059 | DB11986 | 956 | 484 | [
"DDInter1313",
"DDInter648"
] | Norfloxacin | Entrectinib | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
956,
24,
484
]
],
[
[
956,
62,
112
],
[
112,
23,
484
]
],
[
[
956,
40,
1539
],
[
1539,
24,
484
]
],
[
[
956,
24,
774
],
[
774,
2... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Norfloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that co... |
DB00690 | DB09293 | 1,216 | 116 | [
"DDInter762",
"DDInter954"
] | Flurazepam | Iodide I-131 | A benzodiazepine derivative used mainly as a hypnotic. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1216,
24,
116
]
],
[
[
1216,
63,
701
],
[
701,
24,
116
]
],
[
[
1216,
24,
516
],
[
516,
24,
116
]
],
[
[
1216,
40,
1418
],
[
1418,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and ... |
DB00081 | DB00092 | 273 | 58 | [
"DDInter1838",
"DDInter40"
] | Tositumomab | Alefacept | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Moderate | 1 | [
[
[
273,
24,
58
]
],
[
[
273,
64,
1172
],
[
1172,
24,
58
]
],
[
[
273,
24,
384
],
[
384,
63,
58
]
],
[
[
273,
25,
405
],
[
405,
63,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
... | Tositumomab may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and ... |
DB00393 | DB11718 | 854 | 927 | [
"DDInter1295",
"DDInter640"
] | Nimodipine | Encorafenib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
854,
24,
927
]
],
[
[
854,
1,
84
],
[
84,
24,
927
]
],
[
[
854,
24,
1264
],
[
1264,
24,
927
]
],
[
[
854,
63,
1010
],
[
1010,
24... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a mode... | Nimodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could ex... |
DB00445 | DB06168 | 322 | 1,531 | [
"DDInter655",
"DDInter281"
] | Epirubicin | Canakinumab | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
322,
24,
1531
]
],
[
[
322,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
322,
63,
377
],
[
377,
24,
1531
]
],
[
[
322,
24,
1270
],
[
1270,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin ... |
DB00023 | DB00026 | 305 | 1,184 | [
"DDInter127",
"DDInter94"
] | Asparaginase Escherichia coli | Anakinra | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Moderate | 1 | [
[
[
305,
24,
1184
]
],
[
[
305,
24,
1573
],
[
1573,
63,
1184
]
],
[
[
305,
25,
770
],
[
770,
63,
1184
]
],
[
[
305,
25,
676
],
[
676,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with ... |
DB01268 | DB08875 | 1,151 | 1,618 | [
"DDInter1731",
"DDInter262"
] | Sunitinib | Cabozantinib | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1151,
25,
1618
]
],
[
[
1151,
62,
112
],
[
112,
23,
1618
]
],
[
[
1151,
24,
384
],
[
384,
63,
1618
]
],
[
[
1151,
63,
307
],
[
307,
... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idel... |
DB01168 | DB08868 | 1,053 | 1,011 | [
"DDInter1526",
"DDInter737"
] | Procarbazine | Fingolimod | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1053,
25,
1011
]
],
[
[
1053,
21,
28714
],
[
28714,
60,
1011
]
],
[
[
1053,
24,
144
],
[
144,
63,
1011
]
],
[
[
1053,
24,
1136
],
[
11... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Procarbazine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Co... | Procarbazine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fingolimod (Compound)
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingo... |
DB00207 | DB00526 | 1,570 | 1,555 | [
"DDInter157",
"DDInter1355"
] | Azithromycin | Oxaliplatin | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1570,
24,
1555
]
],
[
[
1570,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
1570,
24,
79
],
[
79,
24,
1555
]
],
[
[
1570,
24,
1213
],
[
1213,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Azithromycin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Azithromycin m... |
DB00222 | DB09389 | 245 | 517 | [
"DDInter825",
"DDInter1315"
] | Glimepiride | Norgestrel | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
245,
24,
517
]
],
[
[
245,
24,
52
],
[
52,
24,
517
]
],
[
[
245,
25,
86
],
[
86,
24,
517
]
],
[
[
245,
64,
600
],
[
600,
24,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Glimepiride may lead to a major life threatening interaction when taken with Miconazole and Miconazole may ca... |
DB00078 | DB00446 | 1,172 | 597 | [
"DDInter898",
"DDInter351"
] | Ibritumomab tiuxetan | Chloramphenicol | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1172,
24,
597
]
],
[
[
1172,
24,
1230
],
[
1230,
23,
597
]
],
[
[
1172,
24,
318
],
[
318,
62,
597
]
],
[
[
1172,
24,
599
],
[
599,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ci... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00572 | DB00960 | 85 | 887 | [
"DDInter136",
"DDInter1471"
] | Atropine | Pindolol | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
85,
24,
887
]
],
[
[
85,
24,
819
],
[
819,
40,
887
]
],
[
[
85,
63,
88
],
[
88,
40,
887
]
],
[
[
85,
24,
1121
],
[
1121,
1,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"A... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Atropine... |
DB00514 | DB00765 | 506 | 1,266 | [
"DDInter527",
"DDInter1205"
] | Dextromethorphan | Metyrosine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
506,
24,
1266
]
],
[
[
506,
21,
28658
],
[
28658,
60,
1266
]
],
[
[
506,
24,
662
],
[
662,
24,
1266
]
],
[
[
506,
24,
401
],
[
401,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effec... | Dextromethorphan (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Metyrosine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00860 | DB00880 | 891 | 359 | [
"DDInter1513",
"DDInter360"
] | Prednisolone | Chlorothiazide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
891,
24,
359
]
],
[
[
891,
63,
1577
],
[
1577,
1,
359
]
],
[
[
891,
24,
504
],
[
504,
1,
359
]
],
[
[
891,
21,
28748
],
[
28748,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (... |
DB00401 | DB12267 | 84 | 1,476 | [
"DDInter1298",
"DDInter233"
] | Nisoldipine | Brigatinib | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
84,
24,
1476
]
],
[
[
84,
24,
629
],
[
629,
24,
1476
]
],
[
[
84,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
84,
40,
854
],
[
854,
24... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra... |
DB01128 | DB01611 | 918 | 1,487 | [
"DDInter204",
"DDInter893"
] | Bicalutamide | Hydroxychloroquine | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
918,
24,
1487
]
],
[
[
918,
63,
1520
],
[
1520,
25,
1487
]
],
[
[
918,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
918,
21,
28658
],
[
2865... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Bicalutamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Bicalutamide ... |
DB00969 | DB01072 | 2 | 915 | [
"DDInter52",
"DDInter129"
] | Alosetron | Atazanavir | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
2,
24,
915
]
],
[
[
2,
6,
6017
],
[
6017,
45,
915
]
],
[
[
2,
21,
29052
],
[
29052,
60,
915
]
],
[
[
2,
63,
1684
],
[
1684,
23,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Alosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Alosetron (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Atazanavir (Compound)
Alosetron (Compound) causes Sleep disorder (Side Effect) and Sleep disorder (Side Effect) is caused by Atazanavir (Compound)
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and... |
DB00209 | DB00924 | 352 | 1,405 | [
"DDInter1886",
"DDInter454"
] | Trospium | Cyclobenzaprine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
352,
24,
1405
]
],
[
[
352,
24,
1302
],
[
1302,
1,
1405
]
],
[
[
352,
24,
401
],
[
401,
63,
1405
]
],
[
[
352,
24,
1264
],
[
1264,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction... |
DB00992 | DB01324 | 842 | 178 | [
"DDInter1182",
"DDInter1490"
] | Methyl aminolevulinate (topical) | Polythiazide | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
842,
24,
178
]
],
[
[
842,
24,
674
],
[
674,
40,
178
]
],
[
[
842,
63,
359
],
[
359,
40,
178
]
],
[
[
842,
21,
28714
],
[
28714,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"T... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Methyl aminole... |
DB00662 | DB01148 | 717 | 1,128 | [
"DDInter1873",
"DDInter738"
] | Trimethobenzamide | Flavoxate | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
717,
24,
1128
]
],
[
[
717,
21,
28762
],
[
28762,
60,
1128
]
],
[
[
717,
24,
537
],
[
537,
63,
1128
]
],
[
[
717,
24,
1376
],
[
1376,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effe... | Trimethobenzamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Flavoxate (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00690 | DB06691 | 1,216 | 849 | [
"DDInter762",
"DDInter1155"
] | Flurazepam | Mepyramine | A benzodiazepine derivative used mainly as a hypnotic. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1216,
24,
849
]
],
[
[
1216,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1216,
24,
272
],
[
272,
24,
849
]
],
[
[
1216,
24,
1074
],
[
1074,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and ... |
DB06650 | DB08826 | 1,500 | 1,292 | [
"DDInter1324",
"DDInter489"
] | Ofatumumab | Deferiprone | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1500,
25,
1292
]
],
[
[
1500,
63,
4
],
[
4,
25,
1292
]
],
[
[
1500,
64,
1064
],
[
1064,
25,
1292
]
],
[
[
1500,
25,
375
],
[
375,
... | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
... | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Deferiprone
Ofatumumab may lead to a major life threatening interaction when taken with Cladribine and Cladr... |
DB00615 | DB09074 | 690 | 1,362 | [
"DDInter1589",
"DDInter1327"
] | Rifabutin | Olaparib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
690,
25,
1362
]
],
[
[
690,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
690,
63,
79
],
[
79,
24,
1362
]
],
[
[
690,
64,
168
],
[
168,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cau... | Rifabutin may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a modera... |
DB11767 | DB15091 | 1,583 | 676 | [
"DDInter1643",
"DDInter1901"
] | Sarilumab | Upadacitinib | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1583,
25,
676
]
],
[
[
1583,
62,
1193
],
[
1193,
23,
676
]
],
[
[
1583,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1583,
24,
1129
],
[
1129,... | [
[
[
"Sarilumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Sarilumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Sarilumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and ... |
DB01254 | DB15233 | 1,213 | 1,650 | [
"DDInter484",
"DDInter142"
] | Dasatinib | Avapritinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1213,
25,
1650
]
],
[
[
1213,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1213,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
1213,
25,
982
],
[
982... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexaroten... |
DB00747 | DB06691 | 1,442 | 849 | [
"DDInter1647",
"DDInter1155"
] | Scopolamine | Mepyramine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1442,
24,
849
]
],
[
[
1442,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1442,
24,
272
],
[
272,
24,
849
]
],
[
[
1442,
24,
1116
],
[
1116,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine an... |
DB00791 | DB04865 | 132 | 4 | [
"DDInter1902",
"DDInter1335"
] | Uracil mustard | Omacetaxine mepesuccinate | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
132,
24,
4
]
],
[
[
132,
25,
770
],
[
770,
24,
4
]
],
[
[
132,
24,
496
],
[
496,
63,
4
]
],
[
[
132,
24,
563
],
[
563,
24,
... | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],... | Uracil mustard may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A... |
DB00712 | DB09061 | 1,274 | 1,627 | [
"DDInter763",
"DDInter284"
] | Flurbiprofen | Cannabidiol | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1274,
24,
1627
]
],
[
[
1274,
63,
723
],
[
723,
23,
1627
]
],
[
[
1274,
24,
384
],
[
384,
23,
1627
]
],
[
[
1274,
24,
1613
],
[
1613,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Ide... |
DB00104 | DB11703 | 966 | 405 | [
"DDInter1323",
"DDInter9"
] | Octreotide | Acalabrutinib | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
966,
24,
405
]
],
[
[
966,
24,
1324
],
[
1324,
24,
405
]
],
[
[
966,
25,
1101
],
[
1101,
24,
405
]
],
[
[
966,
24,
1375
],
[
1375,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may... |
DB00372 | DB04908 | 999 | 1,671 | [
"DDInter1793",
"DDInter741"
] | Thiethylperazine | Flibanserin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
999,
24,
1671
]
],
[
[
999,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
999,
24,
407
],
[
407,
63,
1671
]
],
[
[
999,
24,
506
],
[
506,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Opium an... |
DB00880 | DB09564 | 359 | 1,296 | [
"DDInter360",
"DDInter930"
] | Chlorothiazide | Insulin degludec | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
359,
24,
1296
]
],
[
[
359,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
359,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
359,
40,
674
],
[
674,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Metfo... |
DB01174 | DB01284 | 697 | 1,042 | [
"DDInter1442",
"DDInter1782"
] | Phenobarbital | Tetracosactide | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
697,
24,
1042
]
],
[
[
697,
40,
1023
],
[
1023,
24,
1042
]
],
[
[
697,
24,
1683
],
[
1683,
63,
1042
]
],
[
[
697,
63,
1184
],
[
1184,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may... | Phenobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate inte... |
DB00405 | DB09488 | 128 | 103 | [
"DDInter517",
"DDInter23"
] | Dexbrompheniramine | Acrivastine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
128,
24,
103
]
],
[
[
128,
23,
771
],
[
771,
62,
103
]
],
[
[
128,
24,
1405
],
[
1405,
24,
103
]
],
[
[
128,
63,
357
],
[
357,
2... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidas... | Dexbrompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cy... |
DB00083 | DB00798 | 677 | 1,132 | [
"DDInter225",
"DDInter815"
] | Botulinum toxin type A | Gentamicin | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Major | 2 | [
[
[
677,
25,
1132
]
],
[
[
677,
25,
361
],
[
361,
63,
1132
]
],
[
[
677,
25,
1481
],
[
1481,
25,
1132
]
],
[
[
677,
25,
416
],
[
416,
... | [
[
[
"Botulinum toxin type A",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
]
],
[
[
"Botulinum toxin type A",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neo... | Botulinum toxin type A may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Botulinum toxin type A may lead to a major life threatening interaction when taken with Polymyxin B and Polymyxin B may... |
DB00620 | DB09065 | 175 | 760 | [
"DDInter1855",
"DDInter424"
] | Triamcinolone | Cobicistat | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
175,
25,
760
]
],
[
[
175,
63,
1101
],
[
1101,
23,
760
]
],
[
[
175,
24,
555
],
[
555,
23,
760
]
],
[
[
175,
24,
938
],
[
938,
6... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Ne... |
DB00981 | DB09128 | 1,528 | 1,241 | [
"DDInter1463",
"DDInter231"
] | Physostigmine (ophthalmic) | Brexpiprazole | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1528,
24,
1241
]
],
[
[
1528,
63,
543
],
[
543,
24,
1241
]
],
[
[
1528,
24,
1662
],
[
1662,
63,
1241
]
],
[
[
1528,
24,
1264
],
[
1264... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazol... |
DB01010 | DB09083 | 61 | 880 | [
"DDInter622",
"DDInter996"
] | Edrophonium | Ivabradine | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
61,
24,
880
]
],
[
[
61,
24,
1220
],
[
1220,
24,
880
]
],
[
[
61,
24,
1276
],
[
1276,
63,
880
]
],
[
[
61,
63,
1528
],
[
1528,
2... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and... |
DB00570 | DB12141 | 147 | 971 | [
"DDInter1936",
"DDInter817"
] | Vinblastine | Gilteritinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
147,
24,
971
]
],
[
[
147,
24,
112
],
[
112,
23,
971
]
],
[
[
147,
24,
1097
],
[
1097,
24,
971
]
],
[
[
147,
24,
1339
],
[
1339,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan an... |
DB08904 | DB11921 | 375 | 1,019 | [
"DDInter342",
"DDInter492"
] | Certolizumab pegol | Deflazacort | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
375,
25,
1019
]
],
[
[
375,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
375,
23,
1193
],
[
1193,
23,
1019
]
],
[
[
375,
62,
1461
],
[
1461,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluco... |
DB11799 | DB13874 | 627 | 1,501 | [
"DDInter205",
"DDInter639"
] | Bictegravir | Enasidenib | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
627,
24,
1501
]
],
[
[
627,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
627,
63,
1419
],
[
1419,
24,
1501
]
],
[
[
627,
24,
1619
],
[
1619,
... | [
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
DB01284 | DB10316 | 1,042 | 334 | [
"DDInter1782",
"DDInter1248"
] | Tetracosactide | Mumps virus strain B level jeryl lynn live antigen | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Moderate | 1 | [
[
[
1042,
24,
334
]
],
[
[
1042,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1042,
25,
908
],
[
908,
25,
334
]
],
[
[
1042,
63,
589
],
[
589,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Tetracosactide",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Tetracosactide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Tetracosactide may lead to a major life threatening interaction when taken with Golimumab and Goli... |
DB06441 | DB08875 | 936 | 1,618 | [
"DDInter283",
"DDInter262"
] | Cangrelor | Cabozantinib | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
936,
25,
1618
]
],
[
[
936,
24,
41
],
[
41,
63,
1618
]
],
[
[
936,
63,
222
],
[
222,
24,
1618
]
],
[
[
936,
24,
643
],
[
643,
24... | [
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levom... | Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine... |
DB01110 | DB06448 | 86 | 171 | [
"DDInter1209",
"DDInter1087"
] | Miconazole | Lonafarnib | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
86,
24,
171
]
],
[
[
86,
62,
222
],
[
222,
23,
171
]
],
[
[
86,
62,
1601
],
[
1601,
24,
171
]
],
[
[
86,
63,
1351
],
[
1351,
24,... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Miconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Miconazole may cause a minor interaction that can limit clinical effects when taken with Loratadine and Loratadine... |
DB00344 | DB05294 | 1,302 | 1,069 | [
"DDInter1543",
"DDInter1917"
] | Protriptyline | Vandetanib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1302,
25,
1069
]
],
[
[
1302,
21,
28921
],
[
28921,
60,
1069
]
],
[
[
1302,
23,
112
],
[
112,
23,
1069
]
],
[
[
1302,
24,
659
],
[
659... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v}... | Protriptyline (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Vandetanib (Compound)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with... |
DB00900 | DB00911 | 45 | 458 | [
"DDInter544",
"DDInter1811"
] | Didanosine | Tinidazole | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
45,
24,
458
]
],
[
[
45,
24,
112
],
[
112,
1,
458
]
],
[
[
45,
21,
28882
],
[
28882,
60,
458
]
],
[
[
45,
24,
310
],
[
310,
63,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Didanosine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tinidazole (Compound)
Dida... |
DB00685 | DB00741 | 1,299 | 167 | [
"DDInter1887",
"DDInter885"
] | Trovafloxacin | Hydrocortisone | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Major | 2 | [
[
[
1299,
25,
167
]
],
[
[
1299,
25,
1220
],
[
1220,
40,
167
]
],
[
[
1299,
64,
175
],
[
175,
40,
167
]
],
[
[
1299,
25,
870
],
[
870,
... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethason... | Trovafloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Trovafloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Hydrocortisone (Compound)
Trov... |
DB00843 | DB09039 | 479 | 1,670 | [
"DDInter583",
"DDInter629"
] | Donepezil | Eliglustat | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Minor | 0 | [
[
[
479,
23,
1670
]
],
[
[
479,
62,
121
],
[
121,
24,
1670
]
],
[
[
479,
63,
322
],
[
322,
24,
1670
]
],
[
[
479,
24,
594
],
[
594,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fenfluramine"
],
[
... | Donepezil may cause a minor interaction that can limit clinical effects when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirub... |
DB01197 | DB06715 | 1,603 | 239 | [
"DDInter292",
"DDInter1500"
] | Captopril | Potassium Iodide | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Major | 2 | [
[
[
1603,
25,
239
]
],
[
[
1603,
21,
29188
],
[
29188,
60,
239
]
],
[
[
1603,
63,
1274
],
[
1274,
24,
239
]
],
[
[
1603,
40,
610
],
[
610,... | [
[
[
"Captopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Captopril",
"{u} (Compound) causes {v} (Side Effect)",
"Pregnancy"
],
[
"Pregnancy",
"{u} (Side Effect) is caused by {v} (... | Captopril (Compound) causes Pregnancy (Side Effect) and Pregnancy (Side Effect) is caused by Potassium Iodide (Compound)
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00169 | DB00564 | 386 | 1,236 | [
"DDInter367",
"DDInter293"
] | Cholecalciferol | Carbamazepine | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
386,
24,
1236
]
],
[
[
386,
24,
362
],
[
362,
1,
1236
]
],
[
[
386,
24,
1335
],
[
1335,
40,
1236
]
],
[
[
386,
6,
3486
],
[
3486,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Carba... |
DB00218 | DB00322 | 1,176 | 141 | [
"DDInter1247",
"DDInter742"
] | Moxifloxacin | Floxuridine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Minor | 0 | [
[
[
1176,
23,
141
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
141
]
],
[
[
1176,
21,
29425
],
[
29425,
60,
141
]
],
[
[
1176,
1,
872
],
[
872,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Floxuridine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Co... | Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Floxuridine (Compound)
Moxifloxacin (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Floxuridine (Compound)
Moxifloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin m... |
DB00280 | DB12332 | 494 | 1,619 | [
"DDInter575",
"DDInter1626"
] | Disopyramide | Rucaparib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
494,
25,
1619
]
],
[
[
494,
23,
112
],
[
112,
23,
1619
]
],
[
[
494,
24,
259
],
[
259,
24,
1619
]
],
[
[
494,
25,
1662
],
[
1662,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and R... |
DB00692 | DB04835 | 274 | 1,655 | [
"DDInter1448",
"DDInter1125"
] | Phentolamine | Maraviroc | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
274,
24,
1655
]
],
[
[
274,
21,
28792
],
[
28792,
60,
1655
]
],
[
[
274,
63,
1061
],
[
1061,
24,
1655
]
],
[
[
274,
24,
714
],
[
714,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Phentolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder... | Phentolamine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Maraviroc (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exac... |
DB11718 | DB15233 | 927 | 1,650 | [
"DDInter640",
"DDInter142"
] | Encorafenib | Avapritinib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
927,
25,
1650
]
],
[
[
927,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
927,
24,
159
],
[
159,
24,
1650
]
],
[
[
927,
25,
982
],
[
982,
... | [
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacafto... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB00188 | DB06772 | 168 | 310 | [
"DDInter222",
"DDInter259"
] | Bortezomib | Cabazitaxel | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
168,
24,
310
]
],
[
[
168,
24,
973
],
[
973,
24,
310
]
],
[
[
168,
6,
3486
],
[
3486,
45,
310
]
],
[
[
168,
21,
28894
],
[
28894,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Bortezomib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Bortezomib (Comp... |
DB00220 | DB00468 | 798 | 1,424 | [
"DDInter1276",
"DDInter1557"
] | Nelfinavir | Quinine | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
798,
24,
1424
]
],
[
[
798,
6,
21998
],
[
21998,
45,
1424
]
],
[
[
798,
7,
5998
],
[
5998,
46,
1424
]
],
[
[
798,
21,
29316
],
[
29316... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {... | Nelfinavir (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Quinine (Compound)
Nelfinavir (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Quinine (Compound)
Nelfinavir (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)... |
DB01197 | DB11130 | 1,603 | 407 | [
"DDInter292",
"DDInter1344"
] | Captopril | Opium | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1603,
24,
407
]
],
[
[
1603,
63,
104
],
[
104,
24,
407
]
],
[
[
1603,
24,
849
],
[
849,
24,
407
]
],
[
[
1603,
40,
610
],
[
610,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramin... |
DB00792 | DB00836 | 832 | 543 | [
"DDInter1878",
"DDInter1088"
] | Tripelennamine | Loperamide | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
832,
24,
543
]
],
[
[
832,
24,
704
],
[
704,
40,
543
]
],
[
[
832,
64,
675
],
[
675,
24,
543
]
],
[
[
832,
40,
649
],
[
649,
1,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Loperamide (Compound)
Tripelennamine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that ... |
DB06228 | DB12015 | 792 | 1,033 | [
"DDInter1609",
"DDInter53"
] | Rivaroxaban | Alpelisib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
792,
24,
1033
]
],
[
[
792,
24,
738
],
[
738,
24,
1033
]
],
[
[
792,
63,
1335
],
[
1335,
24,
1033
]
],
[
[
792,
64,
859
],
[
859,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxca... |
DB08827 | DB09039 | 990 | 1,670 | [
"DDInter1085",
"DDInter629"
] | Lomitapide | Eliglustat | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
990,
24,
1670
]
],
[
[
990,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
990,
63,
1409
],
[
1409,
24,
1670
]
],
[
[
990,
64,
187
],
[
187,
... | [
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Lomitapide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may c... |
DB00754 | DB08880 | 157 | 1,510 | [
"DDInter696",
"DDInter1771"
] | Ethotoin | Teriflunomide | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
157,
25,
1510
]
],
[
[
157,
62,
608
],
[
608,
23,
1510
]
],
[
[
157,
1,
697
],
[
697,
24,
1510
]
],
[
[
157,
63,
1031
],
[
1031,
... | [
[
[
"Ethotoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ethotoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Ethotoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ethotoin (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could ... |
DB00424 | DB00496 | 19 | 194 | [
"DDInter896",
"DDInter480"
] | Hyoscyamine | Darifenacin | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
19,
24,
194
]
],
[
[
19,
24,
704
],
[
704,
1,
194
]
],
[
[
19,
24,
1511
],
[
1511,
63,
194
]
],
[
[
19,
63,
576
],
[
576,
1,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Darifenacin (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that coul... |
DB08881 | DB09082 | 868 | 659 | [
"DDInter1925",
"DDInter1934"
] | Vemurafenib | Vilanterol | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
868,
24,
659
]
],
[
[
868,
63,
1220
],
[
1220,
23,
659
]
],
[
[
868,
64,
1570
],
[
1570,
24,
659
]
],
[
[
868,
25,
927
],
[
927,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Vemurafenib may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin ... |
DB00704 | DB01206 | 267 | 37 | [
"DDInter1263",
"DDInter1086"
] | Naltrexone | Lomustine | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
267,
24,
37
]
],
[
[
267,
21,
28722
],
[
28722,
60,
37
]
],
[
[
267,
63,
1176
],
[
1176,
23,
37
]
],
[
[
267,
24,
637
],
[
637,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Naltrexone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Na... |
DB01088 | DB09237 | 714 | 1,586 | [
"DDInter908",
"DDInter1045"
] | Iloprost | Levamlodipine | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
714,
24,
1586
]
],
[
[
714,
24,
578
],
[
578,
23,
1586
]
],
[
[
714,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
714,
24,
549
],
[
549,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleu... |
DB00983 | DB01221 | 480 | 1,190 | [
"DDInter776",
"DDInter1007"
] | Formoterol | Ketamine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
480,
24,
1190
]
],
[
[
480,
6,
6017
],
[
6017,
45,
1190
]
],
[
[
480,
21,
28787
],
[
28787,
60,
1190
]
],
[
[
480,
24,
222
],
[
222,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Formoterol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ketamine (Compound)
Formoterol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketamine (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibut... |
DB00889 | DB04946 | 1,133 | 924 | [
"DDInter840",
"DDInter907"
] | Granisetron | Iloperidone | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
1133,
25,
924
]
],
[
[
1133,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1133,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1133,
24,
519
],
[
519,
... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risper... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Granisetron may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when t... |
DB01138 | DB11793 | 804 | 738 | [
"DDInter1726",
"DDInter1297"
] | Sulfinpyrazone | Niraparib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
804,
24,
738
]
],
[
[
804,
24,
466
],
[
466,
63,
738
]
],
[
[
804,
25,
1213
],
[
1213,
24,
738
]
],
[
[
804,
64,
1578
],
[
1578,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib m... |
DB00163 | DB12498 | 1,461 | 76 | [
"DDInter1943",
"DDInter1238"
] | Vitamin E | Mogamulizumab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Minor | 0 | [
[
[
1461,
23,
76
]
],
[
[
1461,
23,
1531
],
[
1531,
24,
76
]
],
[
[
1461,
62,
58
],
[
58,
24,
76
]
],
[
[
1461,
23,
676
],
[
676,
64... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canakinumab"
],
[
... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacep... |
DB00065 | DB12674 | 581 | 975 | [
"DDInter923",
"DDInter1105"
] | Infliximab | Lurbinectedin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
581,
25,
975
]
],
[
[
581,
25,
1488
],
[
1488,
24,
975
]
],
[
[
581,
24,
1613
],
[
1613,
24,
975
]
],
[
[
581,
64,
1560
],
[
1560,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"... | Infliximab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Pegin... |
DB00106 | DB00358 | 618 | 1,010 | [
"DDInter4",
"DDInter1140"
] | Abarelix | Mefloquine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Moderate | 1 | [
[
[
618,
24,
1010
]
],
[
[
618,
23,
112
],
[
112,
62,
1010
]
],
[
[
618,
24,
823
],
[
823,
63,
1010
]
],
[
[
618,
24,
1302
],
[
1302,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Tri... |
DB00675 | DB06212 | 888 | 165 | [
"DDInter1744",
"DDInter1833"
] | Tamoxifen | Tolvaptan | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
888,
24,
165
]
],
[
[
888,
24,
1080
],
[
1080,
1,
165
]
],
[
[
888,
6,
8374
],
[
8374,
45,
165
]
],
[
[
888,
21,
28681
],
[
28681,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Tamoxifen (Compound) causes Hypersensitivity (Side Effect) and Hyperse... |
DB00935 | DB01105 | 223 | 222 | [
"DDInter1368",
"DDInter1665"
] | Oxymetazoline (nasal) | Sibutramine | Oxymetazoline is a member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
223,
24,
222
]
],
[
[
223,
24,
1053
],
[
1053,
64,
222
]
],
[
[
223,
40,
31
],
[
31,
63,
87
],
[
87,
25,
222
]
],
[
[
223,
24,
... | [
[
[
"Oxymetazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Oxymetazoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],... | Oxymetazoline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Oxymetazoline may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Sibutramine
Oxymetazoline... |
DB00283 | DB11859 | 701 | 418 | [
"DDInter395",
"DDInter230"
] | Clemastine | Brexanolone | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
701,
24,
418
]
],
[
[
701,
24,
820
],
[
820,
24,
418
]
],
[
[
701,
35,
1242
],
[
1242,
24,
418
]
],
[
[
701,
24,
820
],
[
820,
6... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that co... |
DB00388 | DB08882 | 1,636 | 1,281 | [
"DDInter1453",
"DDInter1070"
] | Phenylephrine | Linagliptin | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1636,
24,
1281
]
],
[
[
1636,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1636,
21,
29547
],
[
29547,
60,
1281
]
],
[
[
1636,
24,
1529
],
[
1... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Phenylephrine (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Linagliptin (Compound)
Phenylephrine may caus... |
DB06643 | DB08895 | 1,136 | 976 | [
"DDInter500",
"DDInter1825"
] | Denosumab | Tofacitinib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1136,
24,
976
]
],
[
[
1136,
24,
1316
],
[
1316,
64,
976
]
],
[
[
1136,
24,
1011
],
[
1011,
25,
976
]
],
[
[
1136,
63,
1555
],
[
1555,... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to... |
DB01115 | DB09036 | 336 | 812 | [
"DDInter1291",
"DDInter1668"
] | Nifedipine | Siltuximab | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
336,
24,
812
]
],
[
[
336,
24,
792
],
[
792,
24,
812
]
],
[
[
336,
62,
1031
],
[
1031,
24,
812
]
],
[
[
336,
1,
1081
],
[
1081,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theo... |
DB01259 | DB14568 | 392 | 982 | [
"DDInter1024",
"DDInter1000"
] | Lapatinib | Ivosidenib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
392,
25,
982
]
],
[
[
392,
23,
271
],
[
271,
23,
982
]
],
[
[
392,
62,
112
],
[
112,
23,
982
]
],
[
[
392,
63,
1101
],
[
1101,
2... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB00495 | DB00526 | 139 | 1,555 | [
"DDInter1961",
"DDInter1355"
] | Zidovudine | Oxaliplatin | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
139,
24,
1555
]
],
[
[
139,
6,
17404
],
[
17404,
45,
1555
]
],
[
[
139,
74,
141
],
[
141,
24,
1555
]
],
[
[
139,
24,
810
],
[
810,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
Zidovudine (Compound) resembles Floxuridine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exace... |
DB01099 | DB06402 | 1,272 | 1,079 | [
"DDInter744",
"DDInter1756"
] | Flucytosine | Telavancin | A fluorinated cytosine analog that is used as an antifungal agent. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
1272,
24,
1079
]
],
[
[
1272,
63,
91
],
[
91,
1,
1079
]
],
[
[
1272,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
1272,
63,
485
],
[
485,
... | [
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
... | Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin (Compound) resembles Telavancin (Compound)
Flucytosine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Flucytosine may cause a moderate interaction that co... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.